1
|
Düll M, Ries V, Tappenbeck J, Riegel K, Strupf M, Sauer SK, Namer B. Das diabetische Stoffwechselprodukt Methylglyoxal verändert die Erregbarkeit von menschlichen C-Fasern. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- M Düll
- Institut für Physiologie und Pathophysiologie, Friedrich-Alexander-Universität, Erlangen, Germany
| | - V Ries
- Institut für Physiologie und Pathophysiologie, Friedrich-Alexander-Universität, Erlangen, Germany
| | - J Tappenbeck
- Institut für Physiologie und Pathophysiologie, Friedrich-Alexander-Universität, Erlangen, Germany
| | - K Riegel
- Institut für Physiologie und Pathophysiologie, Friedrich-Alexander-Universität, Erlangen, Germany
| | - M Strupf
- Institut für Physiologie und Pathophysiologie, Friedrich-Alexander-Universität, Erlangen, Germany
| | - SK Sauer
- Institut für Physiologie und Pathophysiologie, Friedrich-Alexander-Universität, Erlangen, Germany
| | - B Namer
- Institut für Physiologie und Pathophysiologie, Friedrich-Alexander-Universität, Erlangen, Germany
| |
Collapse
|
2
|
Lahut S, Gispert S, Ömür Ö, Depboylu C, Seidel K, Domínguez-Bautista JA, Brehm N, Tireli H, Hackmann K, Pirkevi C, Leube B, Ries V, Reim K, Brose N, den Dunnen WF, Johnson M, Wolf Z, Schindewolf M, Schrempf W, Reetz K, Young P, Vadasz D, Frangakis AS, Schröck E, Steinmetz H, Jendrach M, Rüb U, Başak AN, Oertel W, Auburger G. Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease. Dis Model Mech 2017; 10:619-631. [PMID: 28108469 PMCID: PMC5451169 DOI: 10.1242/dmm.028035] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Accepted: 01/12/2017] [Indexed: 12/30/2022] Open
Abstract
Parkinson's disease (PD) is a frequent neurodegenerative process in old age. Accumulation and aggregation of the lipid-binding SNARE complex component α-synuclein (SNCA) underlies this vulnerability and defines stages of disease progression. Determinants of SNCA levels and mechanisms of SNCA neurotoxicity have been intensely investigated. In view of the physiological roles of SNCA in blood to modulate vesicle release, we studied blood samples from a new large pedigree with SNCA gene duplication (PARK4 mutation) to identify effects of SNCA gain of function as potential disease biomarkers. Downregulation of complexin 1 (CPLX1) mRNA was correlated with genotype, but the expression of other Parkinson's disease genes was not. In global RNA-seq profiling of blood from presymptomatic PARK4 indviduals, bioinformatics detected significant upregulations for platelet activation, hemostasis, lipoproteins, endocytosis, lysosome, cytokine, Toll-like receptor signaling and extracellular pathways. In PARK4 platelets, stimulus-triggered degranulation was impaired. Strong SPP1, GZMH and PLTP mRNA upregulations were validated in PARK4. When analysing individuals with rapid eye movement sleep behavior disorder, the most specific known prodromal stage of general PD, only blood CPLX1 levels were altered. Validation experiments confirmed an inverse mutual regulation of SNCA and CPLX1 mRNA levels. In the 3'-UTR of the CPLX1 gene we identified a single nucleotide polymorphism that is significantly associated with PD risk. In summary, our data define CPLX1 as a PD risk factor and provide functional insights into the role and regulation of blood SNCA levels. The new blood biomarkers of PARK4 in this Turkish family might become useful for PD prediction.
Collapse
Affiliation(s)
- Suna Lahut
- Experimental Neurology, Goethe University Medical School, Frankfurt/Main 60590, Germany
- NDAL, Boğaziçi University, Istanbul 34342, Turkey
| | - Suzana Gispert
- Experimental Neurology, Goethe University Medical School, Frankfurt/Main 60590, Germany
| | - Özgür Ömür
- Experimental Neurology, Goethe University Medical School, Frankfurt/Main 60590, Germany
- NDAL, Boğaziçi University, Istanbul 34342, Turkey
| | - Candan Depboylu
- Department of Neurology, Philipps University, Baldingerstrasse, Marburg 35043, Germany
| | - Kay Seidel
- Dr Senckenberg Chronomedical Institute, Goethe University, Frankfurt/Main 60590, Germany
| | | | - Nadine Brehm
- Experimental Neurology, Goethe University Medical School, Frankfurt/Main 60590, Germany
| | - Hülya Tireli
- Department of Neurology, Haydarpaşa Numune Training and Research Hospital, Istanbul 34668, Turkey
| | - Karl Hackmann
- Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstrasse 74, Dresden 01307, Germany
| | | | - Barbara Leube
- Institute of Human Genetics, Heinrich Heine University, Düsseldorf 40225, Germany
| | - Vincent Ries
- Department of Neurology, Philipps University, Baldingerstrasse, Marburg 35043, Germany
| | - Kerstin Reim
- Department of Molecular Neurobiology and Center for the Molecular Physiology of the Brain, Max Planck Institute of Experimental Medicine, Göttingen 37075, Germany
| | - Nils Brose
- Department of Molecular Neurobiology and Center for the Molecular Physiology of the Brain, Max Planck Institute of Experimental Medicine, Göttingen 37075, Germany
| | - Wilfred F den Dunnen
- Department of Pathology and Medical Biology, Medical Center, University, Groningen 9700 RB, The Netherlands
| | - Madrid Johnson
- Buchmann Institute for Molecular Life Sciences and Institute for Biophysics, Goethe University, Frankfurt/Main 60438, Germany
| | - Zsuzsanna Wolf
- Haemophilia Centre, Medical Clinic III, Institute of Immunohaematology and Transfusion Medicine, Goethe University, Frankfurt/Main 60590, Germany
| | - Marc Schindewolf
- Department of Internal Medicine, Division of Vascular Medicine and Hemostaseology, Goethe University, Frankfurt 60590, Germany
| | - Wiebke Schrempf
- Division of Neurodegenerative Diseases, Department of Neurology, Technische Universität, Dresden 01307, Germany
| | - Kathrin Reetz
- Department of Neurology, RWTH Aachen University Hospital, Aachen 52074, Germany
| | - Peter Young
- Department of Sleep Medicine and Neuromuscular Disorders, University Hospital Münster, Münster 48149, Germany
| | - David Vadasz
- Department of Neurology, Philipps University, Baldingerstrasse, Marburg 35043, Germany
| | - Achilleas S Frangakis
- Buchmann Institute for Molecular Life Sciences and Institute for Biophysics, Goethe University, Frankfurt/Main 60438, Germany
| | - Evelin Schröck
- Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstrasse 74, Dresden 01307, Germany
| | - Helmuth Steinmetz
- Experimental Neurology, Goethe University Medical School, Frankfurt/Main 60590, Germany
| | - Marina Jendrach
- Experimental Neurology, Goethe University Medical School, Frankfurt/Main 60590, Germany
| | - Udo Rüb
- Dr Senckenberg Chronomedical Institute, Goethe University, Frankfurt/Main 60590, Germany
| | | | - Wolfgang Oertel
- Department of Neurology, Philipps University, Baldingerstrasse, Marburg 35043, Germany
| | - Georg Auburger
- Experimental Neurology, Goethe University Medical School, Frankfurt/Main 60590, Germany
| |
Collapse
|
3
|
Boura E, Stamelou M, Vadasz D, Ries V, Unger MM, Kägi G, Oertel WH, Möller JC, Mylius V. Is increased spinal nociception another hallmark for Parkinson's disease? J Neurol 2017; 264:570-575. [PMID: 28120040 DOI: 10.1007/s00415-016-8390-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 12/29/2016] [Accepted: 12/30/2016] [Indexed: 01/25/2023]
Abstract
Augmented spinal nociception during the "off" phase has been observed early in Parkinson's disease further increasing with disease duration. To find out whether increased spinal nociception represents a premotor feature, experimental pain sensitivity was assessed in idiopathic REM-sleep behavior disorder (IRBD) patients with or without signs of a neurodegenerative disorder compared to early Parkinson's disease (ePD) patients and healthy controls (HC). Spinal nociception as measured by the nociceptive flexion reflex (NFR) and experimental pain sensitivity as measured by heat and electrical pain thresholds were determined in 14 IRBD, 15 ePD patients in the medication-defined "off" state and 27 HC in an explorative cohort study. No significant differences between IRBD and HC were found with regard to spinal nociception (NFR) and experimental pain sensitivity. However, IRBD patient with anosmia and/or abnormal DaTSCAN tended to increased experimental pain sensitivity. In contrast, early PD patients exhibited increased NFR responses compared to HC, and a tendency for increased spinal nociception compared to IRBD patients. Increased spinal nociception may represent an early but not a premotor, non-motor feature of PD. Whether increased pain sensitivity already presents a premotor feature should be assessed in further studies.
Collapse
Affiliation(s)
- Evangelia Boura
- Department of Neurology, Philipps University, Baldingerstrasse, 35043, Marburg, Germany
| | - Maria Stamelou
- Department of Neurology, Philipps University, Baldingerstrasse, 35043, Marburg, Germany.,Second Department of Neurology, Movement Disorders Clinic, University of Athens and Movement Disorders Department, Hygeia Hospital, Athens, Greece
| | - David Vadasz
- Department of Neurology, Philipps University, Baldingerstrasse, 35043, Marburg, Germany
| | - Vincent Ries
- Department of Neurology, Philipps University, Baldingerstrasse, 35043, Marburg, Germany
| | - Marcus M Unger
- Department of Neurology, Philipps University, Baldingerstrasse, 35043, Marburg, Germany.,Department of Neurology, Saarland University, Homburg, Germany
| | - Georg Kägi
- Department of Neurology, Kantonsspital St.Gallen, St. Gallen, Switzerland
| | - Wolfgang H Oertel
- Department of Neurology, Philipps University, Baldingerstrasse, 35043, Marburg, Germany
| | - Jens C Möller
- Department of Neurology, Philipps University, Baldingerstrasse, 35043, Marburg, Germany.,Parkinson Center, Center for Neurological Rehabilitation, Zihlschlacht, Switzerland
| | - Veit Mylius
- Department of Neurology, Philipps University, Baldingerstrasse, 35043, Marburg, Germany. .,Department of Neurology, Kantonsspital St.Gallen, St. Gallen, Switzerland. .,Department of Neurology, Center for Neurorehabilitation, Valens, Switzerland.
| |
Collapse
|
4
|
Rode S, Ries V, Petzold T, Buch U, Untersweg F, Fischer B. Anforderungen und Anwendungshinweise für den Einsatz von Qualitätsindikatoren in der medizinischen Versorgung: Ergebnisse eines systematischen Reviews. Gesundheitswesen 2016; 78:e110-e119. [DOI: 10.1055/s-0042-102347] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- S. Rode
- GeQiK Geschäftsstelle Qualitätssicherung im Krankenhaus bei der Baden-Württembergischen Krankenhausgesellschaft Stuttgart
| | - V. Ries
- Medizinischer Dienst der Krankenversicherung Nordrhein, Leiterin Bildung, Düsseldorf
| | - T. Petzold
- Zentralbereich Qualitäts- und Medizinisches Risikomanagement, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden
| | - U. Buch
- Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen GmbH, Koordination G-BA Gremien, Göttingen
| | - F. Untersweg
- Steiermärkische Krankenanstaltengesellschaften mbH, KAGES-Management/Qualitätsmanagement, Graz
| | - B. Fischer
- Krankenhausgesellschaft Nordrhein-Westfalen, Referat Qualitätsmanagement, IT und Datenanalyse, Düsseldorf
| |
Collapse
|
5
|
Ries V, Vadasz D, Belke M, Oertel W, Knake S. Bildgebende Verfahren als Biomarker der Neurodegeneration bei der REM-Schlafverhaltensstörung. Somnologie 2014. [DOI: 10.1007/s11818-014-0686-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
6
|
Chiu WH, Carlsson T, Depboylu C, Höglinger GU, Oertel WH, Ries V. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease. Neuropharmacology 2013; 79:212-21. [PMID: 24291466 DOI: 10.1016/j.neuropharm.2013.11.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2013] [Revised: 10/15/2013] [Accepted: 11/20/2013] [Indexed: 01/19/2023]
Abstract
Olfactory dysfunction, often preceding the cardinal motor symptoms, such as bradykinesia, rigidity, tremor at rest and postural instability, is frequently reported in Parkinson's disease. This symptom appears to be related to an increased number of dopamine neurons in the periglomerular layer of the olfactory bulb. In animal models of Parkinson's disease, adult neural progenitor cells migrating from the subventricular zone of the lateral ventricle to the olfactory bulb are evidently altered in their survival and progeny. The modulation of neural progenitor cells contributing to the number of dopamine neurons in the periglomerular layer, however, is still poorly understood. In this study, we have investigated the survival and neuronal differentiation of newly generated cells in the olfactory bulb, following treatment with the dopamine precursor l-DOPA and the monoamine oxidase-B inhibitor selegiline in a unilateral, intranigral 6-hydroxydopamine lesion model in mice. Our data show that the number of neural progenitor cells in the subventricular zone is decreased after an intranigral 6-hydroxydopamine lesion, while there is no difference from control in lesioned mice with selegiline or l-DOPA treatment. Selegiline is able to normalize the number of dopamine neurons in the periglomerular layer, while l-DOPA treatment sustains the increased number observed in 6-hydroxydopamine lesioned animals. We conclude that there is a distinct modulation of newly generated dopamine neurons of the olfactory bulb after l-DOPA and selegiline treatment. The differential effects of the two drugs might also play a role in olfactory dysfunction in Parkinson's disease patients.
Collapse
Affiliation(s)
- Wei-Hua Chiu
- Department of Neurology, Experimental Neurology Unit, Philipps-University Marburg, Biomedical Research Center, Hans-Meerwein-Strasse 2, 35043 Marburg, Germany
| | - Thomas Carlsson
- Department of Neurology, Experimental Neurology Unit, Philipps-University Marburg, Biomedical Research Center, Hans-Meerwein-Strasse 2, 35043 Marburg, Germany; Institute of Neurophysiology, Neuroscience Center, Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Candan Depboylu
- Department of Neurology, Experimental Neurology Unit, Philipps-University Marburg, Biomedical Research Center, Hans-Meerwein-Strasse 2, 35043 Marburg, Germany
| | - Günter U Höglinger
- Department of Neurology, Experimental Neurology Unit, Philipps-University Marburg, Biomedical Research Center, Hans-Meerwein-Strasse 2, 35043 Marburg, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Department of Translational Neurodegeneration, Technical University Munich, Max-Lebsche-Platz 30, 81377 Munich, Germany
| | - Wolfgang H Oertel
- Department of Neurology, Experimental Neurology Unit, Philipps-University Marburg, Biomedical Research Center, Hans-Meerwein-Strasse 2, 35043 Marburg, Germany
| | - Vincent Ries
- Department of Neurology, Experimental Neurology Unit, Philipps-University Marburg, Biomedical Research Center, Hans-Meerwein-Strasse 2, 35043 Marburg, Germany.
| |
Collapse
|
7
|
Oertel W, Vadasz D, Ries V, Mayer G, Eggert K, Krenzer M, Unger M, Höglinger G, Mollenhauer B, Sixel-Döring F, Trenkwalder C, Depboylu C. Prodromale Marker der Parkinson-Krankheit. Akt Neurol 2013. [DOI: 10.1055/s-0033-1355379] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- W. Oertel
- Klinik für Neurologie, Philipps-Universität, Marburg
| | - D. Vadasz
- Klinik für Neurologie, Philipps-Universität, Marburg
| | - V. Ries
- Klinik für Neurologie, Philipps-Universität, Marburg
| | - G. Mayer
- Hephata-Klinik, Klinik für Neurologie, Schwalmstadt-Treysa
| | - K. Eggert
- Klinik für Neurologie, Philipps-Universität, Marburg
| | - M. Krenzer
- Klinik für Neurologie, Philipps-Universität, Marburg
| | - M. Unger
- Klinik für Neurologie, Universitätsklinikum des Saarlandes, Homburg/Saar
| | - G. Höglinger
- Klinik für Neurologie, Technische Universität, München
| | - B. Mollenhauer
- Zentrum für Parkinson-Syndrome und Bewegungsstörungen, Paracelsus-Elena Klinik, Kassel
| | - F. Sixel-Döring
- Zentrum für Parkinson-Syndrome und Bewegungsstörungen, Paracelsus-Elena Klinik, Kassel
| | - C. Trenkwalder
- Zentrum für Parkinson-Syndrome und Bewegungsstörungen, Paracelsus-Elena Klinik, Kassel
| | - C. Depboylu
- Klinik für Neurologie, Philipps-Universität, Marburg
| |
Collapse
|
8
|
Kim SR, Ries V, Cheng HC, Kareva T, Oo TF, Yu WH, Duff K, Kholodilov N, Burke RE. Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling. Neurobiol Dis 2011; 44:215-22. [PMID: 21782946 DOI: 10.1016/j.nbd.2011.07.003] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2011] [Revised: 06/27/2011] [Accepted: 07/06/2011] [Indexed: 01/02/2023] Open
Abstract
The mechanisms underlying the chronic neurodegeneration that occurs in Parkinson's disease (PD) are unknown. One emerging hypothesis is that neural systems deteriorate and eventually degenerate due to a primary failure of either extrinsic neurotrophic support or the intrinsic cellular pathways that mediate such support. One of the cellular pathways that have been often identified in mediating neurotrophic effects is that of PI3K/Akt signaling. In addition, recent observations have suggested a primary failure of PI3K/Akt signaling in animal models and in PD patients. Therefore, to explore the possible role of endogenous Akt signaling in maintaining the viability and functionality of substantia nigra (SN) dopamine neurons, one of the principal systems affected in PD, we have used an adeno-associated viral vector to transduce them with a dominant negative (DN) form of Akt, the pleckstrin homology (PH) domain alone (DN(PH)-Akt). In addition, we have examined the effect of DN(PH)-Akt in murine models of two risk factors for human PD: advanced age and increased expression of α-synuclein. We find that transduction of these neurons in normal adult mice has no effect on any aspect of their morphology at 4 or 7weeks. However, in both aged mice and in transgenic mice with increased expression of human α-synuclein we observe decreased phenotypic expression of the catecholamine synthetic enzyme tyrosine hydroxylase (TH) in dopaminergic axons and terminals in the striatum. In aged transgenic α-synuclein over-expressing mice this reduction was 2-fold as great. We conclude that the two principal risk factors for human PD, advanced age and increased expression of α-synuclein, reveal a dependence of dopaminergic neurons on endogenous Akt signaling for maintenance of axonal phenotype.
Collapse
Affiliation(s)
- Sang Ryong Kim
- Department of Neurology, Columbia University, New York, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011; 26:1243-50. [PMID: 21484867 DOI: 10.1002/mds.23616] [Citation(s) in RCA: 148] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2010] [Revised: 11/17/2010] [Accepted: 12/01/2010] [Indexed: 11/08/2022] Open
Abstract
Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa-induced dyskinesia. Two randomized, double-blind, placebo-controlled, parallel-group, in-patient studies for Parkinson's disease patients with moderate to severe levodopa-induced dyskinesia (study 1) and severe levodopa-induced dyskinesia (study 2) on stable dopaminergic therapy were performed. Patients received 25-150 mg AFQ056 or placebo twice daily for 16 days (both studies). Study 2 included a 4-day down-titration. Primary outcomes were the Lang-Fahn Activities of Daily Living Dyskinesia Scale (study 1), the modified Abnormal Involuntary Movement Scale (study 2), and the Unified Parkinson's Disease Rating Scale-part III (both studies). Secondary outcomes included the Unified Parkinson's Disease Rating Scale-part IV items 32-33. The primary analysis was change from baseline to day 16 on all outcomes. Treatment differences were assessed. Fifteen patients were randomized to AFQ056 and 16 to placebo in study 1; 14 patients were randomized to each group in study 2. AFQ056-treated patients showed significant improvements in dyskinesias on day 16 versus placebo (eg, Lang-Fahn Activities of Daily Living Dyskinesia Scale, P = .021 [study 1]; modified Abnormal Involuntary Movement Scale, P = .032 [study 2]). No significant changes were seen from baseline on day 16 on the Unified Parkinson's Disease Rating Scale-part III in either study. Adverse events were reported in both studies, including dizziness. Serious adverse events (most commonly worsening of dyskinesias, apparently associated with stopping treatment) were reported by 4 AFQ056-treated patients in study 1, and 3 patients (2 AFQ056-treated patient and 1 in the placebo group) in study 2. AFQ056 showed a clinically relevant and significant antidyskinetic effect without changing the antiparkinsonian effects of dopaminergic therapy. © 2011 Movement Disorder Society.
Collapse
Affiliation(s)
- Daniela Berg
- University of Tübingen, Hertie-Institute of Clinical Brain Research and German Center for Neurodegenerative Diseases, Tübingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Depboylu C, Chiu WH, Weihe E, Ries V, Oertel WH, Höglinger GU, Schäfer M. Striatal tyrosine hydroxylase expressing neurons in mouse models of Parkinson's disease. Akt Neurol 2009. [DOI: 10.1055/s-0029-1238465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Ries V, Cheng HC, Baohan A, Kareva T, Oo TF, Rzhetskaya M, Bland RJ, During MJ, Kholodilov N, Burke RE. Regulation of the postnatal development of dopamine neurons of the substantia nigra in vivo by Akt/protein kinase B. J Neurochem 2009; 110:23-33. [PMID: 19490361 DOI: 10.1111/j.1471-4159.2009.06101.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Following mitosis, specification and migration during embryogenesis, dopamine neurons of the mesencephalon undergo a postnatal naturally occurring cell death event that determines their final adult number, and a period of axonal growth that determines pattern and extent of target contacts. While a number of neurotrophic factors have been suggested to regulate these developmental events, little is known, especially in vivo, of the cell signaling pathways that mediate these effects. We have examined the possible role of Akt/Protein Kinase B by transduction of these neurons in vivo with adeno-associated viral vectors to express either a constitutively active or a dominant negative form of Akt/protein kinase B. We find that Akt regulates multiple features of the postnatal development of these neurons, including the magnitude of the apoptotic developmental cell death event, neuron size, and the extent of target innervation of the striatum. Given the diversity and magnitude of its effects, the regulation of the development of these neurons by Akt may have implications for the many psychiatric and neurologic diseases in which these neurons may play a role.
Collapse
Affiliation(s)
- Vincent Ries
- Klinik für Neurologie, Universitätsklinikum Giessen und Marburg GmbH, Marburg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Ries V, Silva RM, Oo TF, Cheng HC, Rzhetskaya M, Kholodilov N, Flavell RA, Kuan CY, Rakic P, Burke RE. JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. J Neurochem 2008; 107:1578-88. [PMID: 19014392 DOI: 10.1111/j.1471-4159.2008.05713.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Activation of c-jun N-terminal kinase (JNK) by the mitogen-activated protein kinase cascade has been shown to play an important role in the death of dopamine neurons of the substantia nigra, one of the principal neuronal populations affected in Parkinson's disease. However, it has remained unknown whether the JNK2 and JNK3 isoforms, either singly or in combination, are essential for apoptotic death, and, if so, the mechanisms involved. In addition, it has been unclear whether they play a role in axonal degeneration of these neurons in disease models. To address these issues we have examined the effect of single and double jnk2 and jnk3 null mutations on apoptosis in a highly destructive neurotoxin model, that induced by intrastriatal 6-hydroxydopamine. We find that homozygous jnk2/3 double null mutations result in a complete abrogation of apoptosis and a prolonged survival of the entire population of dopamine neurons. In spite of this complete protection at the cell soma level, there was no protection of axons. These studies provide a striking demonstration of the distinctiveness of the mechanisms that mediate cell soma and axon degeneration, and they illustrate the need to identify and target pathways of axon degeneration in the development of neuroprotective therapeutics.
Collapse
Affiliation(s)
- Vincent Ries
- Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Berger K, Broll S, Winkelmann J, Heberlein I, Müller T, Ries V. Untersuchung zur Reliabilität der deutschen Version des PDQ-39: Ein krankheitsspezifischer Fragebogen zur Erfassung der Lebensqualität von Parkinson-Patienten. Akt Neurol 2008. [DOI: 10.1055/s-2007-1017628] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
14
|
Ries V, Henchcliffe C, Kareva T, Rzhetskaya M, Bland R, During MJ, Kholodilov N, Burke RE. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A 2006; 103:18757-62. [PMID: 17116866 PMCID: PMC1654135 DOI: 10.1073/pnas.0606401103] [Citation(s) in RCA: 138] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Despite promising preclinical studies, neurotrophic factors have not yet achieved an established role in the treatment of human neurodegenerative diseases. One impediment has been the difficulty in providing these macromolecules in sufficient quantity and duration at affected sites. An alternative approach is to directly activate, by viral vector transduction, intracellular signaling pathways that mediate neurotrophic effects. We have evaluated this approach in dopamine neurons of the substantia nigra, neurons affected in Parkinson's disease, by adeno-associated virus 1 transduction with a gene encoding a myristoylated, constitutively active form of the oncoprotein Akt/PKB. Adeno-associated virus Myr-Akt has pronounced trophic effects on dopamine neurons of adult and aged mice, including increases in neuron size, phenotypic markers, and sprouting. Transduction confers almost complete protection against apoptotic cell death in a highly destructive neurotoxin model. Activation of intracellular neurotrophic signaling pathways by vector transfer is a feasible approach to neuroprotection and restorative treatment of neurodegenerative disease.
Collapse
Affiliation(s)
| | | | | | | | | | - Matthew J. During
- Human Cancer Genetics Program, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210
| | | | - Robert E. Burke
- Departments of *Neurology and
- Pathology, Columbia University College of Physicians and Surgeons, New York, NY 10032; and
- To whom correspondence should be addressed at:
Department of Neurology, Room 306, Black Building, Columbia University Medical Center, 650 West 168th Street, New York, NY 10032. E-mail:
| |
Collapse
|
15
|
Silva RM, Ries V, Oo TF, Yarygina O, Jackson-Lewis V, Ryu EJ, Lu PD, Marciniak SJ, Ron D, Przedborski S, Kholodilov N, Greene LA, Burke RE. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem 2005; 95:974-86. [PMID: 16135078 PMCID: PMC3082498 DOI: 10.1111/j.1471-4159.2005.03428.x] [Citation(s) in RCA: 226] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
There is increasing evidence that neuron death in neurodegenerative diseases, such as Parkinson's disease, is due to the activation of programmed cell death. However, the upstream mediators of cell death remain largely unknown. One approach to the identification of upstream mediators is to perform gene expression analysis in disease models. Such analyses, performed in tissue culture models induced by neurotoxins, have identified up-regulation of CHOP/GADD153, a transcription factor implicated in apoptosis due to endoplasmic reticulum stress or oxidative injury. To evaluate the disease-related significance of these findings, we have examined the expression of CHOP/GADD153 in neurotoxin models of parkinsonism in living animals. Nuclear expression of CHOP protein is observed in developmental and adult models of dopamine neuron death induced by intrastriatal injection of 6-hydroxydopamine (6OHDA) and in models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). CHOP is a mediator of neuron death in the adult 60HDA model because a null mutation results in a reduction in apoptosis. In the chronic MPTP model, however, while CHOP is robustly expressed, the null mutation does not protect from the loss of neurons. We conclude that the role of CHOP depends on the nature of the toxic stimulus. For 6OHDA, an oxidative metabolite of dopamine, it is a mediator of apoptotic death.
Collapse
MESH Headings
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/adverse effects
- Animals
- Animals, Newborn
- Apoptosis/drug effects
- Apoptosis/physiology
- Axotomy/methods
- Behavior, Animal
- Blotting, Northern/methods
- Blotting, Western/methods
- Cell Count/methods
- DNA-Binding Proteins/genetics
- DNA-Binding Proteins/metabolism
- Disease Models, Animal
- Dopamine/metabolism
- Female
- Gene Expression Regulation/drug effects
- Gene Expression Regulation/physiology
- Immunohistochemistry/methods
- In Situ Hybridization/methods
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Mutation/physiology
- Neurons/drug effects
- Neurons/metabolism
- Neurons/pathology
- Neurotoxins
- Oxidopamine/toxicity
- Parkinsonian Disorders/etiology
- Parkinsonian Disorders/metabolism
- Parkinsonian Disorders/pathology
- Pregnancy
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Rats
- Regulatory Factor X Transcription Factors
- Reverse Transcriptase Polymerase Chain Reaction/methods
- Substantia Nigra/growth & development
- Substantia Nigra/pathology
- Time Factors
- Transcription Factor CHOP/deficiency
- Transcription Factor CHOP/metabolism
- Transcription Factors/genetics
- Transcription Factors/metabolism
- Tyrosine 3-Monooxygenase/metabolism
Collapse
Affiliation(s)
- Robert M Silva
- Department of Neurology, The College of Physicians and Surgeons, Columbia University, New York 10032, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Oo TF, Ries V, Cho J, Kholodilov N, Burke RE. Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat. J Comp Neurol 2005; 484:57-67. [PMID: 15717300 PMCID: PMC3092474 DOI: 10.1002/cne.20463] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
There is increasing evidence that glial cell line-derived neurotrophic factor (GDNF) plays a role as a limiting, striatal target-derived neurotrophic factor for dopamine neurons of the substantia nigra pars compacta (SNpc) by regulating the magnitude of the first phase of postnatal natural cell death which occurs in these neurons. While it has been shown that GDNF mRNA is relatively abundant in postnatal striatum, the cellular basis of its expression has been unknown. We therefore used nonradioactive in situ hybridization and immunohistochemistry to examine the cellular basis of GDNF mRNA and protein expression, respectively, in postnatal striatum and related structures. We found that GDNF mRNA is expressed within medium-sized striatal neurons. Expression in glia was not observed. At the protein level, regionally, GDNF expression in striatum was observed in striosomal patches, as previously described. At a cellular level a few neurons were observed, but they do not account for the striosomal pattern. This pattern is predominantly due to GDNF-positive neuropil. Some of this neuropil arises from tyrosine hydroxylase-positive nigro-striatal dopaminergic afferents. Astrocytic processes do not appear to contribute to the striosomal pattern. GDNF-positive fibers are identified not only within intrinsic striatal neuropil, but also in fibers within the major striatal efferent targets: the globus pallidus, the entopeduncular nucleus, and the SN pars reticulata. We conclude that during normal postnatal development, medium-sized neurons are the principal source of GDNF within the striatum.
Collapse
Affiliation(s)
- Tinmarla Frances Oo
- Department of Neurology, The College of Physicians and Surgeons, Columbia University, New York, New York 10032
| | - Vincent Ries
- Department of Neurology, The College of Physicians and Surgeons, Columbia University, New York, New York 10032
| | - Jinwhan Cho
- Department of Neurology, The College of Physicians and Surgeons, Columbia University, New York, New York 10032
| | - Nikolai Kholodilov
- Department of Neurology, The College of Physicians and Surgeons, Columbia University, New York, New York 10032
| | - Robert E. Burke
- Department of Neurology, The College of Physicians and Surgeons, Columbia University, New York, New York 10032
- Department of Pathology, The College of Physicians and Surgeons, Columbia University, New York, New York 10032
| |
Collapse
|
17
|
Höglinger GU, Rissling I, Metz A, Ries V, Heinermann A, Prinz H, Spieker S, Deuschl G, Baum E, Oertel WH. Enhancing recognition of early Parkinsonism in the community. Mov Disord 2004; 19:505-12. [PMID: 15133813 DOI: 10.1002/mds.20033] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Because Parkinsonism is underdiagnosed in the community, we have validated screening modalities in the field setting and developed a screening procedure to enhance recognition of undiagnosed patients. In a first survey, we identified suspect cases among patients consulting 9 general practitioners (GPs) over a 3-week period using in parallel: (1) a published questionnaire; (2) a standardized examination by the GPs; (3) clinical impression of the GPs; or (4) pre-established diagnoses. Parkinsonism was ascertained by two neurologists with a 1-year follow-up and FP-CIT-SPECT. In total, 1,411 patients consulted the GPs, 1,030 participated in the study, 87 possible cases were identified by at least one of four screening modalities, 12 suffered from Parkinsonism, and 4 of these 12 were de novo cases. Statistical analysis demonstrated that with appropriate evaluation, the questionnaire is highly sensitive and excludes most nonaffected persons, and that the GPs' clinical impression is more specific. We therefore tested in a second survey the efficacy of a serial screening, starting with the questionnaire, followed by a standardized GP evaluation, and then by neurological examination. Of 1,353 participants seen by 9 GPs during a 3-week period, 5 de novo cases were identified. This simple screening protocol significantly enhances recognition of incipient Parkinsonism.
Collapse
|
18
|
Benamer HTS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MHIM, Sips HJWA, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord 2001; 15:503-510. [DOI: 10.1002/1531-8257(200005)15:3<503::aid-mds1013>3.0.co;2-v] [Citation(s) in RCA: 492] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/1999] [Revised: 12/16/1999] [Accepted: 01/25/2000] [Indexed: 11/11/2022] Open
|
19
|
Gerhard A, Neumaier B, Elitok E, Glatting G, Ries V, Tomczak R, Ludolph AC, Reske SN. In vivo imaging of activated microglia using [11C]PK11195 and positron emission tomography in patients after ischemic stroke. Neuroreport 2000; 11:2957-60. [PMID: 11006973 DOI: 10.1097/00001756-200009110-00025] [Citation(s) in RCA: 102] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Neuroprotective strategies are currently being developed for stroke patients. Although the focus is on the development of early treatment the importance of late pathogenetic events is increasingly recognized. To investigate the microglial reaction in stroke we used a marker for activated microglia, [11C]PK11195, and PET in five patients with ischemic stroke 5-53 days after infarction. In one patient serial measurements were made. We demonstrated in each individual and at each point in time that a microglial reaction takes place in the area where T1 weighted MRI (magnetic resonance imaging) shows intensity changes. We consider this PET method as a promising tool to study the late pathogenetic consequences of cerebral infarction and to evaluate neuroprotective strategies with respect to the consequences of the microglial activation.
Collapse
Affiliation(s)
- A Gerhard
- Neurologische Universitätsklink im Rehabilitationskrankenhaus Ulm, Germany
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15:503-10. [PMID: 10830416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
OBJECTIVE To evaluate whether visual assessment of [123I]-FP-CIT (DaTSCAN, Nycomed Amersham, plc) single photon emission computerized tomography (SPECT) images can differentiate between parkinsonism and essential tremor (ET). METHODS [123I]-FP-CIT SPECT imaging was conducted in a six-center study of 158 patients with a clinical diagnosis of parkinsonism compared with 27 ET cases and 35 healthy volunteers. Striatal uptake of the radioligand was graded normal or abnormal, and abnormal images were further graded to three levels of severity. An institutional read whereby each center visually assessed the images blinded to the clinical data and a consensus blinded read by a panel of five was undertaken. RESULTS The institutional reading scored 154 of 158 cases of parkinsonism abnormal, all 27 cases of ET as normal, and 34 of 35 healthy volunteers as normal compared with the consensus blinded read scoring 150 cases of parkinsonism as abnormal, 25 ET cases as normal, and 33 healthy volunteers as normal. Sensitivity for the clinical diagnosis of parkinsonism was 97% and specificity for ET was 100% for the institutional read, whereas sensitivity was 95% and specificity 93% for the consensus blinded read. Semiquantitative analysis of specific: nonspecific caudate and putamen uptake were consistent with the results of visual inspection. CONCLUSION Visual assessment of [123I]-FP-CIT SPECT images is an easily applied diagnostic test which is helpful in the differential diagnosis of tremor disorders and in confirming a clinical diagnosis of a hypokinetic-rigid syndrome.
Collapse
Affiliation(s)
- T S Benamer
- Department of Neurology, Institute of Neurological Sciences, Glasgow, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Ries V, Hertting G, Jackisch R. Properties of 3,4-diaminopyridine-evoked dopamine and acetylcholine release in rabbit caudate nucleus slices: involvement of facilitatory adenosine A2 receptors or nitric oxide? Brain Res 1996; 743:303-14. [PMID: 9017259 DOI: 10.1016/s0006-8993(96)01102-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The 3H-overflow from slices of the rabbit caudate nucleus preincubated with tritiated dopamine (DA), or choline, and then superfused and stimulated twice with 3,4-diaminopyridine (3,4-DAP; 25 microM, 1 min), was explored as an in vitro model for evoked release of DA, or acetylcholine (ACh), respectively. In both cases the 3,4-DAP-evoked 3H-overflow was tetrodotoxin-sensitive and Ca(2+)-dependent and hence most probably represents action potential-induced exocytotic release of DA or ACh, respectively. Using pairs of preferential agonists/antagonists it was shown, that evoked DA release was inhibited via presynaptic D2 autoreceptors (quinpirole/domperidone) and kappa-opioid receptors (U-50488H/norbinaltorphimine). No evidence was found for the presence of presynaptic adenosine A1 or A2 receptors on dopaminergic terminals. Moreover, 3,4-DAP-evoked DA release was unaffected by increased intracellular cyclic AMP levels or by drugs affecting the NO/guanylate cyclase pathway. In a similar manner it was shown that 3,4-DAP-evoked ACh release was inhibited via presynaptic muscarine autoreceptors (oxotremorine/atropine) and dopamine D2 heteroreceptors (quinpirole/domperidone). Again, no evidence for the involvement of the NO/guanylate cyclase system in the modulation of ACh release was found, whereas the presence of inhibitory adenosine A1 receptors, but not of facilitatory A2 receptors, could be clearly established. It is concluded, that 3,4-DAP-evoked 3H-overflow from rabbit caudate nucleus slices preincubated with [3H]DA or [3H]choline, represents a simple and useful in vitro model for action potential-induced DA or ACh release, respectively. Moreover, at least in this model or rabbit brain region, facilitatory adenosine A2 receptors and the NO/guanylate cyclase system seem not to be involved in the release of these transmitters.
Collapse
Affiliation(s)
- V Ries
- Institute of Pharmacology, University of Freiburg, Germany
| | | | | |
Collapse
|